Medical Management of Heavy Menstrual Bleeding

Johannes Bitzer, Oskari Heikinheimo, Anita L Nelson, Joaquím Calaf, Joaquin Calaf-Alsina, Ian S Fraser
Obstetrical & gynecological survey · 2015 · vol. 70(2) , pp. 115–130 · doi:10.1097/ogx.0000000000000155 · PMID:25671373 · W2008764193
review OA: closed CC0 ⤵ 10 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

The levonorgestrel-releasing intrauterine system is the most effective medical treatment for heavy menstrual bleeding, followed by combined hormonal contraceptives and tranexamic acid.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Importance Heavy menstrual bleeding (HMB) is a common complaint among reproductive-aged women, which negatively affects their health as well as their social, professional, and family lives. Modern medical management usually provides effective control of HMB irrespective of the underlying cause. Surgical interventions should be reserved for women with significant pelvic pathology and those unresponsive to medical therapy. Objective The aim of this review was to provide a comprehensive summary of the efficacy and safety of available medical treatments of HMB. Evidence Acquisition A comprehensive MEDLINE and EMBASE literature search was undertaken using selected terms associated with HMB to identify clinical studies published before March 20, 2013, that reported changes in menstrual blood loss in women receiving medical intervention. Results The effectiveness of treatments to reduce HMB due to endometrial dysfunction in descending order was as follows: (1) the levonorgestrel-releasing intrauterine system (LNG-IUS) (initial release rate of 20 μg of LNG per 24 hours), (2) combined hormonal contraceptives (oral or transvaginal), (3) tranexamic acid, and (4) long-course oral progestogens (≥3 weeks per cycle). The LNG-IUS was found to reduce HMB due to some structural causes (leiomyomas and adenomyosis). The reduction in menstrual blood loss achieved with nonsteroidal anti-inflammatory drugs and short-course oral progestogens (≤14 days per cycle) is less impressive but may be sufficient for women who have marginally increased blood loss. Conclusions and Relevance For women not seeking pregnancy, the LNG-IUS is the first-line medical therapy for HMB, with combined hormonal contraceptives as second choice. For other women, fewer effective options exist. Target Audience Obstetricians and gynecologists, family physicians. Learning Objectives After completing this CME activity, physicians should be better able to describe the most effective medical therapies available for women who present with HMB, to prescribe appropriate therapies based on the women’s fertility needs/requirements, and to identify therapies that may be perceived as effective but in which robust data are lacking.

My notes (saved in your browser only)

Condition tags

adenomyosis

MeSH descriptors

Menorrhagia Antifibrinolytic Agents Antifibrinolytic Agents Anti-Inflammatory Agents, Non-Steroidal Anti-Inflammatory Agents, Non-Steroidal Contraceptives, Oral, Hormonal Contraceptives, Oral, Hormonal Female Humans Intrauterine Devices, Medicated Levonorgestrel Levonorgestrel Menorrhagia Menorrhagia Progestins Progestins Tranexamic Acid Tranexamic Acid

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (100)

Cited by (10)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:18:04.362919+00:00
License: CC0 · commercial use OK